Trial Profile
Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms THE RAGTIME STUDY
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.
- 02 May 2019 Status changed from recruiting to active, no longer recruiting.
- 02 May 2019 Planned End Date changed from 1 Mar 2020 to 30 Apr 2020.